Study on T-Cell Changes After Radiation Therapy Alone and with M9241 in Prostate Cancer Treated with Hormone Therapy

Program Overview

Prostate cancer is often treated with radiation and hormone therapy, but up to 30% of these cancers can return within 5 years. This study is testing a new drug, M9241, to see if it can help the immune system fight prostate cancer better. The main goal is to find safe doses of M9241 and see how it affects the immune system. Participants will be adults with high- or intermediate-risk prostate cancer that hasn't spread. The study will last 7 months and includes screening, treatment, and follow-up visits.

Description

This study is investigating whether a new drug, M9241, can enhance the effects of radiation therapy and hormone therapy in treating prostate cancer. Prostate cancer patients often receive radiation and hormone therapy, but many still experience a return of cancer. M9241 is designed to boost the immune system's ability to fight cancer. The study will test different doses of M9241 to find the safest and most effective amount. Participants will receive standard radiation and hormone therapy, and some will also receive M9241 injections. The study will monitor the immune system's response to these treatments. Participants will undergo various tests, including blood tests, scans, and biopsies, to track their progress. The study aims to improve treatment outcomes for prostate cancer patients by enhancing the body's natural defenses against cancer.

Eligibility Criteria